新型疫苗研发方法。
Novel approaches for vaccine development.
机构信息
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Moderna, Inc., Cambridge, MA, USA.
出版信息
Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.
Abstract
Vaccines are critical tools for maintaining global health. Traditional vaccine technologies have been used across a wide range of bacterial and viral pathogens, yet there are a number of examples where they have not been successful, such as for persistent infections, rapidly evolving pathogens with high sequence variability, complex viral antigens, and emerging pathogens. Novel technologies such as nucleic acid and viral vector vaccines offer the potential to revolutionize vaccine development as they are well-suited to address existing technology limitations. In this review, we discuss the current state of RNA vaccines, recombinant adenovirus vector-based vaccines, and advances from biomaterials and engineering that address these important public health challenges.
摘要
疫苗是维护全球健康的重要工具。传统的疫苗技术已经广泛应用于各种细菌和病毒病原体，但也有一些例子表明它们并不成功，例如持续性感染、具有高度序列变异性的快速进化病原体、复杂的病毒抗原和新兴病原体。新型技术，如核酸和病毒载体疫苗，具有改变疫苗开发的潜力，因为它们非常适合解决现有技术的局限性。在这篇综述中，我们讨论了 RNA 疫苗、重组腺病毒载体疫苗的现状，以及生物材料和工程学方面的进展，这些进展都有助于应对这些重要的公共卫生挑战。
相似文献
1
Novel approaches for vaccine development.新型疫苗研发方法。
Cell. 2021 Mar 18;184(6):1589-1603. doi: 10.1016/j.cell.2021.02.030.
2
Messenger RNA vaccines against SARS-CoV-2.针对 SARS-CoV-2 的信使 RNA 疫苗。
Cell. 2021 Mar 18;184(6):1401. doi: 10.1016/j.cell.2020.12.039. Epub 2021 Jan 13.
3
COVID-19 mRNA vaccines.COVID-19 mRNA 疫苗。
J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.
4
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BA.2.12.1、BA.4和BA.5亚变体的加强mRNA疫苗的持久性
N Engl J Med. 2022 Oct 6;387(14):1329-1331. doi: 10.1056/NEJMc2210546. Epub 2022 Sep 7.
5
Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.脂质纳米颗粒 COVID-19 mRNA 疫苗的长期稳定性和免疫原性受颗粒大小的影响。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2342592. doi: 10.1080/21645515.2024.2342592. Epub 2024 May 7.
6
Engineering mRNA vaccine with broad-spectrum protection against SARS-cov-2 variants.设计具有针对SARS-CoV-2变体的广谱保护作用的mRNA疫苗。
Biochem Biophys Res Commun. 2025 Feb;746:151224. doi: 10.1016/j.bbrc.2024.151224. Epub 2024 Dec 25.
7
The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.纳米颗粒助力 COVID-19 mRNA 疫苗的成功，微针平台为大流行疫苗应对带来新希望。
DNA Cell Biol. 2022 Jan;41(1):25-29. doi: 10.1089/dna.2021.0538. Epub 2021 Dec 24.
8
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations.mRNA及自我扩增mRNA疫苗纳米制剂的设计与开发。
Nanomedicine (Lond). 2024;19(30):2699-2725. doi: 10.1080/17435889.2024.2419815. Epub 2024 Nov 13.
9
Safety of mRNA-Based Vaccines for SARS CoV-2.mRNA 疫苗在 SARS-CoV-2 中的安全性。
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
10
Introduction to RNA Vaccines Post COVID-19.新冠疫情后的RNA疫苗介绍
Methods Mol Biol. 2024;2786:1-22. doi: 10.1007/978-1-0716-3770-8_1.
引用本文的文献
1
Computational identification of membrane proteins for vaccine design against drug-resistant Moraxella catarrhalis.用于设计抗耐药性卡他莫拉菌疫苗的膜蛋白的计算鉴定
Mol Genet Genomics. 2025 Sep 6;300(1):92. doi: 10.1007/s00438-025-02288-w.
2
Codon Usage Evolution in Viruses: Implications for Survival and Pathogenicity.病毒中的密码子使用进化：对生存和致病性的影响
J Mol Evol. 2025 Sep 4. doi: 10.1007/s00239-025-10263-7.
3
Method validation and assessment of the biodistribution and shedding for adenovirus vector-based vaccine using qPCR and dPCR.使用定量聚合酶链反应（qPCR）和数字聚合酶链反应（dPCR）对基于腺病毒载体的疫苗进行方法验证以及生物分布和脱落评估。
Mol Ther Methods Clin Dev. 2025 Aug 5;33(3):101549. doi: 10.1016/j.omtm.2025.101549. eCollection 2025 Sep 11.
4
Optimizing Immunization Strategies for Individuals Living with HIV: A Review of Essential Vaccines, Vaccine Coverage, and Adherence Factors.优化艾滋病毒感染者的免疫策略：基本疫苗、疫苗接种率及依从性因素综述
Vaccines (Basel). 2025 Jul 28;13(8):798. doi: 10.3390/vaccines13080798.
5
Nanotechnology-based mRNA vaccines.基于纳米技术的mRNA疫苗。
Nat Rev Methods Primers. 2023;3(1). doi: 10.1038/s43586-023-00246-7. Epub 2023 Aug 17.
6
mRNA Vaccine Development in the Fight Against Zoonotic Viral Diseases.用于对抗人畜共患病毒性疾病的mRNA疫苗研发
Viruses. 2025 Jul 8;17(7):960. doi: 10.3390/v17070960.
7
Latest advances and prospects in the pathogenesis, animal models, and vaccine research of severe fever with thrombocytopenia syndrome virus.发热伴血小板减少综合征病毒发病机制、动物模型及疫苗研究的最新进展与展望
Front Immunol. 2025 Jun 26;16:1624290. doi: 10.3389/fimmu.2025.1624290. eCollection 2025.
8
TransMA: an explainable multi-modal deep learning model for predicting properties of ionizable lipid nanoparticles in mRNA delivery.TransMA：一种用于预测可电离脂质纳米颗粒在mRNA递送中性质的可解释多模态深度学习模型。
Brief Bioinform. 2025 May 1;26(3). doi: 10.1093/bib/bbaf307.
9
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.肺癌中基于新抗原的免疫疗法：进展、挑战与前景
Cancers (Basel). 2025 Jun 12;17(12):1953. doi: 10.3390/cancers17121953.
10
Vaccines for preventing infections in adults with haematological malignancies.用于预防血液系统恶性肿瘤成人感染的疫苗。
Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2.
本文引用的文献
1
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.基于信使核糖核酸的严重急性呼吸综合征冠状病毒2候选疫苗CVnCoV可诱导高水平的病毒中和抗体并在啮齿动物中发挥保护作用。
NPJ Vaccines. 2021 Apr 16;6(1):57. doi: 10.1038/s41541-021-00311-w.
2
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.将生物材料学和免疫学相结合以提高传染病疫苗的效力
ACS Biomater Sci Eng. 2020 Feb 10;6(2):759-778. doi: 10.1021/acsbiomaterials.9b01255. Epub 2020 Jan 12.
5
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
6
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
7
Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal.葡萄牙儿童使用 B 群脑膜炎球菌疫苗与 B 群侵袭性脑膜炎球菌病的关联。
JAMA. 2020 Dec 1;324(21):2187-2194. doi: 10.1001/jama.2020.20449.
8
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.加速研究的实施：在乌干达开展的 Ad26.ZEBOV、MVA-BN-Filo 两剂次埃博拉疫苗临床试验中应用的实施策略。
Glob Health Action. 2020 Dec 31;13(1):1829829. doi: 10.1080/16549716.2020.1829829.
9
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.COVID-19 疫苗领跑者及其纳米技术设计。
ACS Nano. 2020 Oct 27;14(10):12522-12537. doi: 10.1021/acsnano.0c07197. Epub 2020 Oct 9.
10
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.两种异源 HIV 疫苗方案在健康、未感染 HIV 的成年人中的安全性和免疫原性（TRAVERSE）：一项随机、平行分组、安慰剂对照、双盲、1/2a 期研究。
Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0.
Zotero 插件